Welcome to our newsroom. Here you will find all the latest news about Bristol Myers Squibb in Belgium. As a journalist, you will also find all press releases, contact details and visual material here.

Latest news

RECONNECT, talent stays, even after cancer >

Aware of the specificity of cancer, the Foundation Against Cancer launched RECONNECT, a free online platform to guide human resources or other managers in the reintegration process of employees diagnosed with cancer.

Informative session immunotherapy
Innovation in healthcare: interview with Voka Health Community >

Sabine De Beuf, BMS Head of Corporate Affairs & Patient Advocacy Benelux, and Lieven De Maesschalck, Thomas More Innovation Manager at Mobilab & Care, shared their vision on innovation in healthcare during a duo interview with Voka. This is part of a series of interviews with new and long-standing members to celebrate 10th anniversary of Voka Health Community.

Topping-off ceremony
Bristol Myers Squibb celebrates highest point in first European cell therapy production facility construction at Leiden Bio Science Park >

The construction of the CAR T cell therapy production centre of Bristol Myers Squibb in the Leiden Bio Science Park (LBSP) is nearing completion. Today the highest point was reached which traditionally means a topping-off ceremony. 

For all media inquiries

Sabine de Beuf
Contact us for more information or to receive press material.


Sabine de Beuf

Head of Corporate Communications, Public Affairs & Patient Advocacy


Phone number: +32 2 352 76 11




If you are not a member of the press and have a non-media related question then find the right contact information here. This will enable us to help you faster!

Corporate Publications

In short

Who are we?

Learn more about the mission, vision and values of Bristol Myers Squibb Belgium

Facts and figures

The most important facts and figures at a glance

Our medicines

More information about the medicines distributed by Bristol Myers Squibb in Belgium

Our Research

Get an overview of our research for innovative medicines